ArticleCancer management and research2019

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China.

Ruxu You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.